Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of XNW34017 in advanced solid tumors
CTR20254803Phase 2Active
- Sponsor
- Sinovent
- Start
- Jan 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of XNW34017 in Nonhematologic neoplasms, sponsored by Sinovent. Started Jan 2026; status: active.
02
Drugs
XNW34017
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254803.